刘卫彬，王化冰，许贤豪.重症肌无力//王维治.神经病学.第2版.北京：人民卫生出版社，2013：1509-1544.

吴江.神经病学.北京：人民卫生出版社，2005.

许贤豪.神经免疫学.湖北科学技术出版社，2000：91-150.

Akira S.Functional roles of STAT family proteins：lessons from knockout mice.Stem Cells，1999，17（3）：138-146.

Ahlberg R，Yi Q，Pirskanen R，et al.Treatment of myasthenia gravis with anti-CD4antibody：improvement correlates to decreased T-cell autoreactivity.Neurology，1994，44：1732-1737.

Adikari SB，Lian H，Link H，et al.Interferon-gamma-modi ed dendritic cells suppress B cell function and ameliorate the development of experimental autoimmune myasthenia gravis.Clin Exp Immunol.2004.138：230-236.

Bai Y，Liu R，Huang D，et al.CCL2recruitment of IL-6-producing CD11b＋monocytes to the draining lymph nodes during the initiation of Th17-dependent B cell-mediated autoimmunity.Eur J Immunol，2008，38（7）：1877-1888.

Bromberg MB.Myasthenia gravis and myasthenic syndromes.In Motor disorders.D.S.Younger，editor.Lippincott Williams ＆Wilkins.Philadelphia：Pennsylvania，2005：231-246.

Balasa B，Deng C，Lee J，et al.The Th1cytokine IL-4is not required for the progression of antibody-dependent autoimmune myasthenia gravis.J.Immunol，1998，161：2856-2862.

Berman PW，Patrick J.Experimental myasthenia gravis：a murine system.J Exp Med，1980，151：204-223.

Balandina A，Lécart S，Dartevelle P，et al.Functional defect of regulatory CD4（＋）CD25＋T cells in the thymus of patients with autoimmune myasthenia gravis.Blood，2005，105：735-741.

Conti-Fine BM，Milani M，Kaminski HJ.Myasthenia gravis：past，present，and future.J Clin Invest，2006，116（11）：2843-2854.

Christadoss P，Goluszko E.Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein.J Neuroimmunol，2002，122： 186-190.

Christadoss P，Lindstrom JM，Melvold RW，et al.Mutation at I-A beta chain prevents experimental autoimmune myasthenia gravis.Immunogenetics，1985，21：33-38.

Cavalcante P，Le Panse R，Berrih-Aknin S，et al.The thymus in myasthenia gravis：Site of"innate autoimmunity"？Muscle Nerve，2011，44（4）：467-484.

Delpy L，Douin-Echinard V，Garidou L，et al.Estrogen enhances susceptibility to experimental autoimmune myasthenia gravis by promoting type 1-polarized immune responses.J.Immunol，2005，175：5050-5057.

Duan RS，Adikari SB，Huang YM，et al.Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modi ed dendritic cells.Neurobiol Dis，2004，16：461-467.

Dau PC，Lindstrom JM，Cassel CK，et al.Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis.N Engl J Med，1977，297（21）：1134-1140.

Eng H，Lefvert AK，Mellstedt H，et al.Human monoclonal immunoglobulins that bind the human acetylcholine receptor.Eur J Immunol，1987，17：1867-1869.

Feferman T，Maiti PK，Berrih-Aknin S，et al.Overexpression of IFN-induced protein 10and its receptor CXCR3in myasthenia gravis.J.Immunol，2005，174：5324-5331.

Lin F，Kaminski HJ，Conti-Fine BM，et al.Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection.J Clin Invest，2002，110（9）：1269-1274.

Goluszko E，Deng C，Poussin MA，et al.Tumor necrosis factor receptor p55and p75deficiency protects mice from developing experimental autoimmune myasthenia gravis.J.Neuroimmunol，2002，122：85-93.

Glass DJ，Dechiara TM，Stitt，TN，et al.The receptor tyrosine kinase MuSK is required for neuromuscular junction formation and is a functional receptor for agrin.Cold Spring Harb Symp Quant Biol，1996，61：435-444.

Hohlfeld R，Toyka KV，Heininger K，et al Autoimmune human T lymphocytes specific for acetylcholine receptor.Nature，1984，310：244-246.

Hohlfeld R，Engel AG.Induction of HLA-DR expression on human myoblasts with interferongamma.Am J Pathol，1990，136：503-508.

Horton RM，Manfredi AA，Conti-Tronconi BM.The‘embryonic’gamma subunit of the nicotinic acetylcholine receptor is expressed in adult extraocular muscle.Neurology，1993，43：983-986.

Hoch W，McConville J，Helms S，et al.Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor anti-bodies.Nat Med，2001，7：365-368.

Hughes BW，Kusner LL，Kaminski HJ.Molecular architecture of the neuromuscular junction.Muscle Nerve，2006，33：445-461.

Im SH，Barchan D，Maiti PK，et al.Suppression of experimental myasthenia gravis，a B cell-mediated autoimmune disease，by blockade of IL-18.FASEB J，2001，15：2140-2148.

Jander S，Stoll G.Increased serum levels of the interferon-gamma-inducing cytokine interleukin-18in myasthenia gravis.Neurology，2002，59：287-289.

Joachim P，Schreiter C，Segura JM，et al.Acetylcholine Receptor Organization in Membrane Domains in Muscle Cells.J Biol Chem，2011，286（1）：363-369.

Kaminski HJ，Li Z，Richmonds C，et al.Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis.Exp.Neurol，2004，189：333-342.

Karachunski PI，Ostlie NS，Monfardinic，et al.Absence of IFN-gamma or IL-12has different effects on experimental myasthenia gravis in C57BL/6 mice.J Immunol，2000，164：5236-5244.

Kaul R，Shenoy M，Goluszko E，et al.Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis.J.Immunol，1994，152：3152-3157.

Kaul R，Shenoy M，Christadoss P.The role of major histocompatibility complex genes in myasthenia gravis and experimental autoimmune myasthenia gravis pathogenesis.Adv.Neuroimmunol，1994，4：387-402.

Kim JY，Park KD.Treatment of myasthenia gravis based on its immunopathogenesis.J Clin Neurol，2011，7（4）：173-183.

Liu R，La Cava A，Bai XF，et al.Cooperation of invariant NKT cells and CD4＋CD25＋T regulatory cells in the prevention of autoimmune myasthenia.J Immunol，2005，175：7898-7904.

Liu R，Zhou Q，La Cava A，et al.Expansion of regulatory T cells via IL-2/anti-IL-2mAb complexes suppresses experimental myasthenia.Eur J Immunol，2010，40（6）：1577-1589.

Liszewski MK，Post TW，Atkinson JP.Membrane cofactor protein（MCP or CD46）：newest member of the regulators of complement activation gene cluster.Annu Rev Immunol，1991，9：431-455.

Lane RJ，Roncaroli F，Charles P，et al.Acetylcholine receptor antibodies in patients with genetic myopathies：clinical and biological significance.Neuromuscul Disord，2012，22（2）：122-128.

Lindstrom JM，Engel AG，Seybold ME，et al.Pathological mechanisms in experimental autoimmune myasthenia gravis.II.Passive transfer of experimental autoimmune myasthenia gravis in rats with antiacetylcholine recepotr antibodies.J Exp Med，1976，144（3）：739-753.

Meriggioli MN.Strategies for treating autoimmunity：novel insights from experimental myasthenia gravis.Ann N Y Acad Sci，2008，1132：276-282.

Meri S，Waldmann H，Lachmann PJ.Distribution of protectin（CD59），a complement membrane attack inhibitor，in normal human tissues.Lab Invest，1991，65：532-537.

Morgutti M，Conti-Tronconi BM，Sghirlanzoni A，et al.Cellular immune response to acetylcholine receptor in myasthenia gravis：II.Thymectomy and corticosteroids.Neurology，1979，29：734-738.

Medof ME，Walter EI，Rutgers JL，et al.Identification of the complement decay-accelerating factor（DAF）on epithelium and glandular cells and in body fluids.J.Exp.Med，1987，165：848-864.

McConville J，Farrugia ME，Beeson D，et al.Detection and characterization of MuSK antibodies in seronegative myasthenia gravis.Ann Neurol，2004，55：580-584.

Nessi V，Nava S，Ruocco C，et al.Naturally occurring CD4＋CD25＋regulatory T cells prevent but do not improve experimental myasthenia gravis.J Immunol，2010，185（9）：5656-5667.

Ostlie N，Milani M，Wang W，et al.Absence of IL-4facilitates the development of chronic autoimmune myasthenia gravis in C57BL/6mice.J Immunol，2003，170：604-612.

Ohta K，Shigemoto K，Kubo S，et al.MuSK antibodies in AChR Ab-seropositive MG vs AChR Ab-seronegative MG.Neurology，2004，62：2132-2133.

Piddlesden SJ，Jiang S，Levin JL，et al.Soluble complement receptor 1（sCR1）protects against experimental autoimmune myasthenia gravis.J.Neuroimmunol，1996，71：173-177.

Protti MP，Manfredi AA，Straub C，et al.Immuno-dominant regions for T helper-cell sensitization on the human nicotinic receptor alpha subunit in myasthenia gravis.Proc Natl Acad Sci USA，1990，87：7792-7796.

Poussin MA，Goluszko E，David CS，et al.HLA-DQ6transgenic mice resistance to experimental autoimmune myasthenia gravis is linked to reduced acetylcholine receptor-specific IFN-gamma，IL-2and IL-10production.J Autoimmun，2001，17：175-180.

Saoudi A，Bernard I，Hoedemaekers A，et al.Experimental autoimmune myasthenia gravis may occur in the context of a polarized Th1-or Th1-type immune response in rats.J Immunol，1999，162：7189-7197.

Shi FD，Wang HB，Li H，et al.Natural killer cells determine the outcome of B cell-mediated autoimmunity.Na Immunol，2000，1：245-251.

Shi FD，Ljunggren HG，La Cava A，et al.Organ-specific features of natural killer cells.Nat Rev Immunol，2011，11（10）：658-671.

Sigoillot SM，Bourgeois F，Lambergeon M，et al.ColQ controls postsynaptic differentiation at the neuromuscular junction.J Neurosci，2010，30（1）：13-23.

Shigemoto K，Kubo S，Marugama N，et al.Induction of myasthenia gravis by immunization against muscle-specific kinase.J.Clin.Invest，2006，116：1016-1024.

Shiraishi H，Motomura M，Yoshimura T，et al.Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis.Ann.Neurol，2005，57：289-293.

Sun Y，Qiao J，Lu CZ，et al.Increase of circulating CD4 ^＋CD25 ^＋T cells in myasthenia gravis patients with stability and thymectomy.Clin.Immunol，2004，112：284-289.

Vernet-der Garabedian B，Lacokova M，Eymard B，et al.Association of neonatal myasthenia gravis with antibodies against the fetal acetylcholine receptor.J Clin Invest，1994，94（2）：555-559.

Vincent A.Unravelling the pathogenesis of myasthenia gravis.Nat Rev Immunol，2002，2（10）：797-804.

Vincent A，McConville J，Farrugia ME，et al.Seronegative myasthenia gravis.Semin.Neurol，2004，24：125-133.

Vincent A，Leite MI.Neuromuscular junction autoimmune disease：muscle specific kinase antibodies and treatments for myasthenia gravis.Curr Opin Neurol，2005，18：519-525.

Wang ZY.Karachunski PI，Howard JF Jr，et al.Myasthenia in SCID mice grafted with myasthenic patient lymphocytes：role of CD4 ^＋and CD8 ^＋cells.Neurology，1999，52：484-497.

Wang ZY，Okita DK，Howard JF Jr.et al.T-cell recognition of muscle acetylcholine receptor subunits in generalized and ocular myasthenia gravis.Neurology，1998，50：1045-1054.

Wang ZY，Diethelm-Okita B，Okita DK，et al.T cell recognition of muscle acetylcholine receptor in ocular myasthenia gravis.J.Neuroimmunol，2000，108：29-39.

Wang HB，Li H，Shi FD，et al.Tumor necrosis factor receptor-1is critically involved in the development of experimental autoimmune myasthenia gravis.Int.Immunol，2000，12：1381-1388.

Wang W，Milani M，Ostlie N，et al.C57BL/6 mice genetically deficient in IL-12/IL-23and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis，suggesting a pathogenic role of non-Th1cells.J Immunol，2007，178（11）：7072-7080.

Weiner HL.Induction and mechanism of action of transforming growth factor-beta-secreting Th3regulatory cells.Immunol.Rev，2001，182：207-214.

Xiao BG，Duan RS，Zhu WH，et al.The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis.Cell Immunol，2006，241：95-101.

Yates A，Bergmann C，Van Hemmen JL，et al.Cytokine-modulated regulation of helper T cell populations.J Theor Biol，2000，206：539-560.

Yang H，Goluszko E，David C，et al.Induction of myasthenia gravis in HLA transgenic mice by immunization with human acetylcholine receptors.Ann N Y Acad Sci，2003，998：375-378.

Yang H，Zhang Y，Wu M，et al.Suppression of ongoing experimental autoimmune myasthenia gravis by transfer of RelB-silenced bone marrow dentritic cells is associated with a change from a T helper Th17/Th1to a Th1and FoxP3regulatory T-cell prole.Inamm Res，2010，59：197-205.